Jia Xiangen, Zhang Guozhi
North China University of Science and Technology Affiliated Hospital, Tangshan, China.
North China University of Science and Technology, Tangshan, China.
Front Genet. 2022 Aug 25;13:961018. doi: 10.3389/fgene.2022.961018. eCollection 2022.
Hepatocellular carcinoma (HCC) is notorious for its high mortality and incidence. Accumulating evidence confirms that chromatin regulators (CRs) have a significant impact on cancer. Therefore, exploring the mode of action and prognostic value of CRs is imminent for the treatment of hepatocellular carcinoma. Transcriptome and clinical data for this study have been downloaded from TCGA (https://portal.gdc.cancer.gov/) and ICGC (https://dcc.icgc.org/). Univariate analysis was used to screen CRs with prognostic value, and our prognostic risk score signature was developed using least absolute shrinkage along with selection operator (lasso) Cox regression analysis. The CRs-based prognostic model was constructed in the TCGA dataset, and low-risk HCC patients had a better prognosis, which was finally validated in the ICGC dataset. We used the receiver operating characteristic curve to identify the accuracy of the prediction model and establish a line chart to prove the clinical effectiveness of the model. We also discussed the differences in drug sensitivity CellMiner database, tumor immune microenvironment ssGSEA algorithm, and clinical characteristics among different risk groups. A prognostic model consisting of seven CRs was constructed and verified in HCC patients. Furthermore, we found that this risk score prognostic signature could independently predict the prognosis of HCC patients. Functional enrichment analysis revealed that CRs are mainly associated with cancer-related signaling pathways and metabolic pathways. In addition, immune cell abundance correlates with risk score levels In brief, we systematically explored the mode of action of CRs in HCC patients and established a reliable prognostic prediction model.
肝细胞癌(HCC)因其高死亡率和高发病率而臭名昭著。越来越多的证据证实,染色质调节因子(CRs)对癌症有重大影响。因此,探索CRs的作用模式和预后价值对于肝细胞癌的治疗迫在眉睫。本研究的转录组和临床数据已从TCGA(https://portal.gdc.cancer.gov/)和ICGC(https://dcc.icgc.org/)下载。采用单因素分析筛选具有预后价值的CRs,并使用最小绝对收缩选择算子(lasso)Cox回归分析建立我们的预后风险评分特征。在TCGA数据集中构建了基于CRs的预后模型,低风险HCC患者预后较好,最终在ICGC数据集中得到验证。我们使用受试者工作特征曲线来确定预测模型的准确性,并建立折线图来证明模型的临床有效性。我们还讨论了不同风险组之间在药物敏感性(CellMiner数据库)、肿瘤免疫微环境(ssGSEA算法)和临床特征方面的差异。构建了一个由七个CRs组成的预后模型并在HCC患者中进行了验证。此外,我们发现这种风险评分预后特征可以独立预测HCC患者的预后。功能富集分析表明,CRs主要与癌症相关信号通路和代谢通路相关。此外,免疫细胞丰度与风险评分水平相关。简而言之,我们系统地探索了CRs在HCC患者中的作用模式,并建立了一个可靠的预后预测模型。